Akcea Therapeutics Inc (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals Inc (NASDAQ: IONS), has received marketing authorisation approval for TEGSEDI (inotersen) in the European Union, the company said on Wednesday.
The European Commission (EC) approved the drug for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin (hATTR) amyloidosis.
An inherited, progressive disease, hATTR amyloidosis is caused by a mutation in the transthyretin (TTR) gene that leads to the abnormal formation and aggregation of TTR protein, resulting in TTR amyloid deposits throughout the body.
TEGSEDI is designed to block production of the TTR protein. In the Phase 3 NEURO-TTR study, treatment with TEGSEDI produced substantial reductions in the levels of the TTR protein regardless of mutation type or stage of disease.
The EC decision means that TEGSEDI is now the world's first and only RNA-targeted therapeutic approved for patients with hATTR amyloidosis, according to Akcea CEO Paula Soteropoulos.
"We are ready to launch TEGSEDI along with our patient and physician support services across Europe," Soteropoulos added.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial